Dosing of a bispecific antibody that binds pd1 and ctla4
AssigneeXencor, Inc.
InventorsBarbara Hickingbottom, Paul Foster
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods for treating a solid cancerous cancer through administering a bispecific anti-PD1 x anti-CTLA4 antibody.
Claims8
A method for treating a solid cancerous tumor in a human subject, comprising:
- administering to the human subject having the solid cancerous tumor an intravenous dose, once every 13-15 days, of between about 0.05 mg/kg and about 12 mg/kg of a bispecific antibody comprising a first monomer comprising SEQ ID NO:
- 1, a second monomer comprising SEQ ID NO:
- 2, and a light chain comprising SEQ ID NO:
- 3 for a time period sufficient to treat the solid cancerous tumor.
The method of a preceding claim, wherein the intravenous dose is:
- between about 0.05 mg/kg and about 0.25 mg/kg;
- or
- between about 0.2 mg/kg and about 0.4 mg/kg;
- or
- between about 0.5 mg/kg and about 1.5 mg/kg;
- or
- between about 2.0 mg/kg and about 4.0 mg/kg;
- or
- between about 8.0 mg/kg and about 12.0 mg/kg.
The method of a preceding claim, wherein the intravenous dose is between about 0.15 mg/kg and about 10.0 mg/kg.
The method of a preceding claim, wherein the administering of the intravenous dose to the human subject is between about 45 minutes and about 75 minutes.
The method of a preceding claim, wherein the time period sufficient to treat the cancer is between about 3 weeks and about 9 weeks.
The method of a preceding claim, further comprising, prior to the administering, assessing the weight of the human subject.
Dependencies are inferred from the claim text.